

Special Issue

From Genes to Systems: Genetic and Epigenetic Control of the Metastatic Cascade

Message from the Guest Editor

We would like to invite you to contribute to this Special Issue of *Genes*, entitled “From Genes to Systems: Genetic and Epigenetic Control of the Metastatic Cascade”. Cancer metastasis remains the leading cause of cancer-related death, and it is increasingly recognized as a process driven not only by genetic alterations but also by epigenetic reprogramming. Tumor cells can reprogram stromal, vascular, and immune partners to establish supportive niches, while circulating tumor cells (CTCs) serve as metastasis-initiating intermediates capable of surviving in circulation, undergoing dormancy, and reactivating at distant organs. This Special Issue will bring together research that unravels the genetic and epigenetic mechanisms underpinning known stages of the metastatic cascade. Topics of interest include tumor heterogeneity, lineage plasticity, metastatic niche formation, dormancy, CTC biology, immune evasion, therapy resistance, and integrative multi-omics analyses. Both foundational research studies and translational research aimed at biomarker discovery, therapeutic targeting, and metastasis interception are welcome.

Guest Editor

Dr. Eric Rahrman
The Hormel Institute, University of Minnesota, Austin, MN 55912, USA

Deadline for manuscript submissions

15 October 2026

G C A T
T A C G
G C A T

Genes

an Open Access Journal
by MDPI

Impact Factor 2.8
CiteScore 5.5
Indexed in PubMed



mdpi.com/si/251478

Genes
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
genes@mdpi.com

[mdpi.com/journal/
genes](https://mdpi.com/journal/genes)



G C A T
T A C G
G C A T

Genes

an Open Access Journal
by MDPI

Impact Factor 2.8
CiteScore 5.5
Indexed in PubMed



[mdpi.com/journal/
genes](https://mdpi.com/journal/genes)



About the Journal

Message from the Editor-in-Chief

Genes is central to our understanding of biology, and modern advances such as genomics and genome editing have maintained genetics as a vibrant, diverse and fast-moving field. There is a need for good quality, open access journals in this area, and the *Genes* team aims to provide expert manuscript handling, serious peer review, and rapid publication across the whole discipline of genetics. Starting in 2010, the journal is now well established and recognised. Why not consider *Genes* for your next genetics paper?

Editor-in-Chief

Prof. Dr. Selvarangan Ponnazhagan
Experimental Cancer Therapeutics, The University of Alabama at
Birmingham, 1825 University Blvd., SHEL 814, Birmingham, AL 35294-
2182, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

Journal Rank:

JCR - Q2 (Genetics and Heredity) / CiteScore - Q2 (Genetics (clinical))